Cavernous Transformation of Portal Vein: Etiology, Diagnosis, Management and Prognosis

NCT02505113 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2015-10-29

No results posted yet for this study

Summary

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

Conditions

  • Portal Vein, Cavernous Transformation Of

Interventions

DRUG

Montelukast

Montelukast (10mg, q.d., p.o.)

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Zaibo Jiang, MD · Sun Yat-sen University

Eligibility

Min Age
1 Year
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02505113 on ClinicalTrials.gov